Go Pro
→ Barricks gold output fell from 2 million ounces to 719000 (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$0.36
$0.40
$0.35
▼
$1.22
$22.62M1.3964,597 shs96,364 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.04
$1.46
$1.13
▼
$2.89
$87.62M0.28724,802 shs446,569 shs
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
$1.06
$1.32
$0.73
▼
$4.88
$73.78M1.27953,911 shs664,270 shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$7.09
$6.92
$2.20
▼
$9.33
$88.46M1.49136,211 shs44,781 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.00%-0.25%-5.59%-42.86%-64.00%
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.00%+25.15%+32.47%+56.92%+31.61%
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
0.00%+8.17%+0.95%-34.97%-77.20%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
0.00%+13.44%-0.70%-13.01%+188.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$0.36
$0.40
$0.35
▼
$1.22
$22.62M1.3964,597 shs96,364 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.04
$1.46
$1.13
▼
$2.89
$87.62M0.28724,802 shs446,569 shs
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
$1.06
$1.32
$0.73
▼
$4.88
$73.78M1.27953,911 shs664,270 shs
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$7.09
$6.92
$2.20
▼
$9.33
$88.46M1.49136,211 shs44,781 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
0.00%-0.25%-5.59%-42.86%-64.00%
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.00%+25.15%+32.47%+56.92%+31.61%
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
0.00%+8.17%+0.95%-34.97%-77.20%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
0.00%+13.44%-0.70%-13.01%+188.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
2.00
Hold$5.381,393.06% Upside
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.50
Moderate Buy$7.67275.82% Upside
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
2.67
Moderate Buy$4.00277.36% Upside
NeurAxis, Inc. stock logo
NRXS
NeurAxis
3.00
Buy$13.0083.36% Upside

Current Analyst Ratings Breakdown

Latest CTSO, NRXS, LUNG, and NNOX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/13/2026
Pulmonx Corporation stock logo
LUNG
Pulmonx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/8/2026
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/7/2026
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
Alliance Global Partners logo
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral$5.00 ➝ $3.00
7/6/2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/22/2026
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$37.22M0.61N/AN/A$0.09 per share4.00
Pulmonx Corporation stock logo
LUNG
Pulmonx
$90.50M0.97N/AN/A$1.31 per share1.56
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
$13.02M5.67N/AN/A$2.01 per share0.53
NeurAxis, Inc. stock logo
NRXS
NeurAxis
$4.28M20.66N/AN/A($0.27) per share-26.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$8.20M-$0.29N/A12.00N/A-48.94%-309.53%-40.60%N/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$54M-$1.16N/AN/AN/A-55.03%-96.66%-38.32%N/A
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
-$75.02M-$1.58N/AN/AN/A-716.44%-70.96%-62.26%8/11/2026 (Estimated)
NeurAxis, Inc. stock logo
NRXS
NeurAxis
-$14.63M-$0.81N/AN/AN/A-492.76%N/A-641.25%8/11/2026 (Estimated)

Latest CTSO, NRXS, LUNG, and NNOX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026N/A
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
-$0.1633N/AN/AN/A$5.39 millionN/A
8/11/2026N/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
-$0.32N/AN/AN/A$2.00 millionN/A
8/6/2026Q2 2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.04-$0.07-$0.03-$0.07$9.39 million$9.63 million
7/29/2026Q2 2026
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.28-$0.24+$0.04-$0.24$22.39 million$22.76 million
6/25/2026Q1 2026
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
N/A-$0.16N/A-$0.20N/A$4.31 million
5/13/2026Q1 2026
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
N/AN/AN/AN/AN/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
4.70
1.09
0.81
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.95
4.32
3.52
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
N/A
3.64
3.40
NeurAxis, Inc. stock logo
NRXS
NeurAxis
N/A
0.24
0.23

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
21.49%
NeurAxis, Inc. stock logo
NRXS
NeurAxis
11.77%

Insider Ownership

CompanyInsider Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
7.80%
Pulmonx Corporation stock logo
LUNG
Pulmonx
7.50%
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
N/A
NeurAxis, Inc. stock logo
NRXS
NeurAxis
21.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
22062.84 million57.94 millionOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25042.95 million39.73 millionOptionable
Nano-X Imaging Ltd. stock logo
NNOX
Nano-X Imaging
19069.60 millionN/AOptionable
NeurAxis, Inc. stock logo
NRXS
NeurAxis
1912.48 million6.09 millionNot Optionable

Recent News About These Companies

NeurAxis Announces Additional Mid-Atlantic Coverage for IB-Stim PENFS Therapy, Expanding Access to Over 500,000 Lives
August 4, 2026  |  quiverquant.comQ
NeurAxis Expands Payer Coverage with New Policies
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338132/0/en/neuraxis-expands-payer-coverage-with-new-policies.html
NeurAxis, Inc. to Report Second Quarter 2026 Financial Results on August 11 and Host Conference Call
July 28, 2026  |  quiverquant.comQ
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334108/0/en/neuraxis-to-host-second-quarter-2026-results-and-business-update-call-on-tuesday-august-11-2026.html
NeurAxis Declares Q2 Stock Dividend on Series B
July 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuraxis-declares-q2-stock-dividend-on-series-b?utm_source=marketbeat.com&utm_medium=referral
Neuraxis (NRXS) Stock Forecast & Price Target
June 17, 2026  |  investing.comhttps://www.investing.com/equities/neuraxis-consensus-estimates
NeurAxis Stockholders Approve Directors and Equity Compensation Plans
June 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neuraxis-stockholders-approve-directors-and-equity-compensation-plans?utm_source=marketbeat.com&utm_medium=referral
NeurAxis Earnings Call Highlights Growth and Hurdles
May 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NRXS-A/pressreleases/2056905/neuraxis-earnings-call-highlights-growth-and-hurdles/
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum
May 18, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/neuraxis-nrxs-climbs-on-reimbursement-and-guideline-momentum-1757204/
NeurAxis Stock Gains Post Q1 Earnings, Revenues and Margin Surge Y/Y
May 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/neuraxis-stock-gains-post-q1-162300872.html
NeurAxis, Inc. (AMEX:NRXS) Q1 2026 Earnings Call Transcript
May 13, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/neuraxis-inc-amexnrxs-q1-2026-earnings-call-transcript-1761092/
NeurAxis, Inc. (NRXS) Q1 2026 Earnings Call Transcript
May 12, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4903364-neuraxis-inc-nrxs-q1-2026-earnings-call-transcript
NeurAxis, Inc.: NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
May 12, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68469075-neuraxis-inc-neuraxis-reports-record-first-quarter-2026-financial-results-driven-by-80-year-over-year-revenue-growth-399.htm
NeurAxis, Inc. Reports 80% Revenue Growth in Q1 2026 Driven by CPT Code Assignment and Expanded Product Adoption
May 12, 2026  |  quiverquant.comQ
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3292697/0/en/neuraxis-reports-record-first-quarter-2026-financial-results-driven-by-80-year-over-year-revenue-growth.html
Earnings To Watch: Neuraxis Inc (NRXS) Reports Q1 2026 Result
May 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/earnings-watch-neuraxis-inc-nrxs-132302638.html
This Small-Cap Healthcare Stock Is Up 300% in a Year and Is Quickly Gaining a Following
May 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/small-cap-healthcare-stock-300-154003142.html
NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287475/0/en/neuraxis-to-host-first-quarter-2026-results-and-business-update-call-on-tuesday-may-12-2026.html
NeurAxis (NRXS) price target increased by 29.41% to 11.22
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/neuraxis-nrxs-price-target-increased-by-2941-to-1122/ar-AA21UIgT
Neuraxis, Inc. Common Stock (NRXS)
April 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/nrxs/pre-market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Trading screen displaying a candlestick price chart, options calls and puts pricing table, and green call, red put buttons.
The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
By Bridget Bennett | July 20, 2026
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
Dutch Bros iced coffee cup with logo in foreground of a Dutch Bros drive-thru location at sunset.
Why Dutch Bros Plunged Despite a Q2 Earnings Beat and Record Revenue
By Jessica Mitacek | August 9, 2026
Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$0.36 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$0.36 +0.00 (+0.28%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$2.04 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$2.04 0.00 (-0.25%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Nano-X Imaging stock logo

Nano-X Imaging NASDAQ:NNOX

$1.06 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$1.06 0.00 (-0.38%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nano-X Imaging Ltd. develops a commercial-grade tomographic imaging device with a digital X-ray source. The company provides teleradiology services and develops artificial intelligence applications to be used in real-world medical imaging applications. Its X-ray source is based on a digital micro-electro-mechanical systems semiconductor cathode. The company's solutions include Nanox Multi Source System comprising Nanox.ARC, a medical tomographic imaging system incorporating its digital X-ray source, and Nanox. CLOUD, a platform which employs a matching engine to match medical images to radiologists that provides image repository, connectivity to diagnostic assistive AI systems, billing, and reporting. It also offers Nanox.MARKETPLACE, which connects imaging facilities with radiologists and enables radiologists to provide, as well as customers to obtain remote interpretations of imaging data; artificial intelligence (AI)-based software imaging solutions to hospitals, health maintenance organizations, integrated delivery networks, pharmaceutical companies, and insurers that are designed to identify or predict undiagnosed or underdiagnosed medical conditions through the mining of data included in images of existing computed tomography scans for osteoporosis and cardiovascular disease; Teleradiology Services, which provide imaging interpretation services for radiology practices, hospitals, medical clinics, diagnostic imaging centers, urgent care facilities; and multi-specialty physician groups, contracts, and radiology readings. The company is headquartered in Petach Tikva, Israel.

NeurAxis stock logo

NeurAxis NASDAQ:NRXS

$7.09 0.00 (0.00%)
Closing price 08/7/2026 04:00 PM Eastern
Extended Trading
$7.12 +0.03 (+0.35%)
As of 08/7/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas